6-溴-2-甲基氨基吡啶 | 89026-79-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-溴-2-甲基氨基吡啶
• 中文别名: 6-溴-2-甲氨基吡啶
• 英文名称: 6-bromo-N-methylpyridin-2-amine
• 英文别名: 6-bromo-2-(methylamino)pyridine；6-bromo-N-methylpyridine-2-amine
• CAS: 89026-79-9
• 化学式: C₆H₇BrN₂
• mdl: MFCD09261221
• 分子量: 187.039
• InChiKey: LYEPZCPAEZKSKN-UHFFFAOYSA-N

物化性质

• 熔点：
  62-63 °C
• 沸点：
  271.9±25.0 °C(Predicted)
• 密度：
  1.581±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光，惰性气体环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-2-methylaminopyridine
Synonyms: 6-Bromo-N-methylpyridin-2-amine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-2-methylaminopyridine
CAS number: 89026-79-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7BrN2
Molecular weight: 187.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-2-甲基氨基吡啶 在 10% Pd on charcoal 、 氢气 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 6.0h， 以100%的产率得到2-(甲氨基)吡啶
  参考文献：
  名称：

  Synthesis of Large Macrocyclic Azacalix[n]pyridines (n = 6 − 9) and Their Complexation with Fullerenes C₆₀ and C₇₀

  摘要：

  Large methylazacalix[n]pyridines (n = 6-9) were synthesized effectively from the Pd-catalyzed macrocyclic fragment coupling reactions between alpha,omega-dibrominated and alpha,omega-diaminated linear oligomers. As macrocyclic host molecules, they formed a 1:1 complex with fullerenes C-60 and C-70 with association constants ranging from 3 x 10(4) to 1 x 10(5) M-1.

  DOI：

  10.1021/ol800840m
• 作为产物：
  描述：

  tert-butyl (6-bromopyridin-2-yl)(methyl)carbamate 在 三氟乙酸 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 20.0h， 以100%的产率得到6-溴-2-甲基氨基吡啶
  参考文献：
  名称：

  [EN] NOVEL COMPOUNDS THAT MODULATE PPARgamma TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
  [FR] NOUVEAUX COMPOSES QUI MODULENT LES RECEPTEURS DE TYPE PPAR DOLLAR G(G) ET UTILISATIONS DE CEUX-CI DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES

  摘要：

  该发明涉及与下列一般式（I）相对应的新化合物：（I），以及用于制备它们的方法，以及它们在用于人类或兽医药物组合物中的用途（在皮肤病学以及心血管疾病、免疫疾病和/或与脂质代谢有关的疾病领域），或者在化妆品组合物中的用途。

  公开号：

  WO2004113331A1
• 作为试剂：
  描述：

  2,6-二溴吡啶 、 甲胺 在 水 、 disodium;carbonate 、 二氯甲烷 、 magnesium sulfate 、 正庚烷 、 6-溴-2-甲基氨基吡啶 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 6-溴-2-甲基氨基吡啶
  参考文献：
  名称：

  NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPARy TYPE RECEPTORS AND COSMETIC/PHARMACEUTICAL COMPOSITIONS COMPRISED THEREOF

  摘要：

  具有一般式(I)的新型双芳香族化合物及其所包含的化妆品/药物组合物在人类或兽医学领域（在皮肤科以及心血管疾病、免疫疾病和/或与脂质代谢有关的疾病领域）中非常有用，或者在化妆品组合物中使用。

  公开号：

  US20120121527A1

文献信息

• [EN] BENZOSULFONYL COMPOUNDS<br/>[FR] COMPOSÉS DE BENZOSULFONYLE
  申请人：VIVACE THERAPEUTICS INC

  公开号：WO2019040380A1

  公开（公告）日：2019-02-28

  Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

  本文提供了包含所述化合物的用于治疗癌症的药物组合物。具体的癌症包括那些由YAP/TAZ介导或由YAP/TAZ与TEAD相互作用调节的癌症。
• INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
  申请人：Lazuli, Inc.

  公开号：US20180244648A1

  公开（公告）日：2018-08-30

  Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

  揭示了αvβ6整合素的小分子抑制剂，以及使用它们治疗多种疾病和症状的方法。
• [EN] INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS<br/>[FR] INDOLYL-PIPÉRIDINYL BENZYLAMINES INHIBITRICES DE LA BÊTA-TRYPTASE
  申请人：SANOFI SA

  公开号：WO2011079102A1

  公开（公告）日：2011-06-30

  The present invention discloses and claims a series of substituted indolyl-piperidinyl benzylamines of formula (I), wherein R1, R2 and R3 are as described herein. More specifically, the compounds of this invention are inhibitors of β-tryptase and are, therefore, useful as pharmaceutical agents. Additionally, this invention also discloses methods of preparation of substituted indolyl-piperidinyl benzylamines. In one of the embodiments, there is provided the compounds of formula (I) wherein R3 is (II).

  本发明公开并要求一系列取代的吲哚基-哌啶基苄胺化合物，其公式为（I），其中R1、R2和R3如本文所述。更具体地说，本发明的化合物是β-tryptase的抑制剂，因此可用作药物制剂。此外，本发明还公开了取代的吲哚基-哌啶基苄胺的制备方法。在其中一个实施例中，提供了公式（I）的化合物，其中R3是（II）。
• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：giraFpharma LLC

  公开号：US20190106427A1

  公开（公告）日：2019-04-11

  Heterocyclic compounds as Wee1 inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了作为Wee1抑制剂的杂环化合物。这些化合物可能被用作治疗剂，用于治疗疾病，并且可能在肿瘤学中发挥特定作用。